Improved potency of cisplatin by hydrophobic ion pairing

被引:30
作者
Feng, LI
De Dille, A
Jameson, VJ
Smith, L
Dernell, WS
Manning, MC
机构
[1] HTD BioSyst Colorado, Loveland, CO 80538 USA
[2] Colorado State Univ, James L Voss Vet Teaching Hosp, Anim Canc Ctr, Ft Collins, CO 80523 USA
[3] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA
关键词
cisplatin; ion pairing; increased potency; cell culture; partition behavior;
D O I
10.1007/s00280-004-0840-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cisplatin is one of the most widely used and effective chemotherapeutic drugs ever discovered against certain forms of cancer. However, its use is limited by toxicity. A more potent form might allow lower doses to be used and would diminish the toxicity. A new analog of cisplatin has been synthesized by stoichiometric replacement of the chloride ligands with the anionic surfactant, Aerosol OT (AOT). The new compound has a very low aqueous solubility ( about 2 mg/l) and a log P value of 2.17, which is more than 4 log units higher than cisplatin itself, indicating a dramatic increase in hydrophobicity. While hydrophobic cisplatin analogs have been synthesized previously, this is the first one with readily dissociable ligands replacing the chlorides. The resultant AOT complex is able to penetrate cellular membranes more efficiently, resulting in a threefold to fivefold increase in intracellular platinum levels. These increased intracellular concentrations correlate with lower IC50 values in a number of cancer and normal cell lines. These findings suggest that further development of the AOT complex as a chemotherapeutic agent is warranted, given its marked increase in potency over the parent compound.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 23 条
[1]   Apparent interaction of dimethyl sulfoxide with cisplatin released from polymer delivery devices injected subcutaneously in dogs [J].
Dernell, WS ;
Straw, RC ;
Withrow, SJ ;
Powers, BE ;
Fujita, SM ;
Yewey, GS ;
Joseph, KF ;
Dunn, RL ;
Whitman, SL ;
Southard, GL .
JOURNAL OF DRUG TARGETING, 1998, 5 (05) :391-396
[2]   Intensive and timely chemotherapy, the key of success in testicular cancer [J].
Fléchon, A ;
Culine, S ;
Droz, JP .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) :35-46
[3]   CELLULAR ACCUMULATION OF THE ANTICANCER AGENT CISPLATIN - A REVIEW [J].
GATELY, DP ;
HOWELL, SB .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1171-1176
[4]   Is cisplatin-induced cell death always produced by apoptosis? [J].
Gonzalez, VM ;
Fuertes, MA ;
Alonso, C ;
Perez, JM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :657-663
[5]   Current clinical practices for ovarian cancers [J].
Harper, P .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :3-6
[6]   Structure, recognition, and processing of cisplatin-DNA adducts [J].
Jamieson, ER ;
Lippard, SJ .
CHEMICAL REVIEWS, 1999, 99 (09) :2467-2498
[7]   Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B [J].
Jamieson, ER ;
Jacobson, MP ;
Barnes, CM ;
Chow, CS ;
Lippard, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (18) :12346-12354
[8]  
JENNERWEIN M, 1995, DRUG METAB DISPOS, V23, P178
[9]   Evolution of cisplatin-based chemotherapy in non-small cell lung cancer - A historical perspective and the eastern cooperative oncology group experience [J].
Johnson, DH .
CHEST, 2000, 117 (04) :133S-137S
[10]   Molecular mechanisms involved in cisplatin cytotoxicity [J].
Jordan, P ;
Carmo-Fonseca, M .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (8-9) :1229-1235